Chung Johnathon, Walterscheid Brooke, Lopez-Vera Jose, Rashid Hytham, Liang Mike K
Department of Internal Medicine, University of Houston/HCA Houston Healthcare Kingwood, TX, USA.
Department of Surgery, University of Houston/HCA Houston Healthcare Kingwood, TX, USA.
HCA Healthc J Med. 2023 Apr 28;4(2):205-208. doi: 10.36518/2689-0216.1451. eCollection 2023.
Mitomycin C (MMC) is a common chemotherapeutic agent used to treat a variety of solid tumors. Cutaneous adverse events are rare, but MMC is a known vesicant reported to cause tissue necrosis and sloughing, erythema, and ulceration if incorrectly infused into the subcutaneous tissue. Definitive treatment of extravasation injuries due to MMC depends on the severity of the cutaneous manifestation, which includes stopping the infusion, removing the catheter, or possible debridement.
We present the case of a 70-year-old female with extensive soft-tissue injury secondary to extravasation of MMC that required hospital admission and surgical intervention to remove the implantable venous access device.
Extravasation injuries caused by vesicant drugs, such as MMC, often present as local skin irritation and inflammation. MMC extravasation may present a wide range of skin and soft tissue manifestations, ranging from erythema to ulcerations to necrosis. This rare but potentially detrimental complication of chemotherapy infusions should be recognized in cancer patients.
丝裂霉素C（MMC）是一种用于治疗多种实体瘤的常用化疗药物。皮肤不良事件较为罕见，但MMC是一种已知的发泡剂，据报道，如果错误地注入皮下组织，会导致组织坏死、脱落、红斑和溃疡。MMC所致外渗损伤的明确治疗取决于皮肤表现的严重程度，包括停止输注、拔除导管或可能进行清创。
我们报告一例70岁女性患者，因MMC外渗继发广泛软组织损伤，需要住院并进行手术干预以取出植入式静脉通路装置。
由发泡剂药物如MMC引起的外渗损伤通常表现为局部皮肤刺激和炎症。MMC外渗可能出现广泛的皮肤和软组织表现，从红斑到溃疡再到坏死。癌症患者应认识到这种化疗输注罕见但可能有害的并发症。
